Core Points - Emergent BioSolutions announced the retirement of Dr. Louis W. Sullivan from its Board of Directors effective November 14, after 19 years of service [1][2] - Dr. Sullivan has been a significant figure in guiding the company through critical decisions, particularly during its multi-year transformation [2] - The company has a mission focused on protecting and saving lives, providing solutions for various health threats [3] Company Overview - Emergent BioSolutions has been operational for over 25 years, preparing for public health challenges and delivering life-saving solutions against threats like smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [3] - The company emphasizes its commitment to public health and community preparedness for current and future health threats [3] Leadership Transition - Dr. Sullivan served on the Board since 2006, holding roles such as chair of the compensation committee and member of the nominating and corporate governance committee [2] - His background includes leadership positions in healthcare and government, notably as president of Morehouse School of Medicine and Secretary of the Department of Health and Human Services [2]

Core Viewpoint - Emergent BioSolutions Inc. will host a conference call on October 29, 2025, to discuss its financial results for the third quarter of 2025 [1]. Group 1: Conference Call Details - The conference call will take place at 5:00 pm eastern time [1]. - Participants can access the call via webcast or by visiting the Investors page of Emergent's website [2]. - Telephone participants must register in advance to receive a confirmation email with details on how to join the call, including a unique passcode and registrant ID [2]. Group 2: Company Overview - Emergent BioSolutions has been operational for over 25 years, focusing on public health protection [4]. - The company provides life-saving solutions for various health threats, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4]. - Emergent aims to prepare communities for current health challenges and future threats [4].

Core Points - Emergent BioSolutions Inc. will be added to the Russell 3000 Index effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes [1][2] - The inclusion in the Russell 3000 Index is seen as a significant milestone in the company's transformation, indicating positive momentum and positioning for sustainable growth [2] - The Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks ranked by total market capitalization, with membership in the Russell 3000 Index providing automatic inclusion in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index [2] Company Overview - Emergent BioSolutions has been focused on delivering protective and life-saving solutions for various health threats for over 25 years, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [5] - The company emphasizes its commitment to strong execution, financial stability, and long-term value creation for shareholders [2] Industry Context - Russell indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies, with approximately $10.5 trillion in assets benchmarked against the Russell U.S. indexes as of December 2023 [3]

Core Insights - Emergent BioSolutions Inc. announced participation in several upcoming investor conferences, indicating active engagement with the investment community [1][3]. Company Overview - Emergent BioSolutions has a mission to protect and save lives, focusing on delivering solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [2]. Upcoming Events - The company will participate in the RBC Global Healthcare Conference on May 20, 2025, with a fireside chat scheduled for 3:35 pm ET, available for virtual attendees via webcast [3]. - Emergent will also present at the Goldman Sachs Leveraged Finance Conference on May 29, 2025, in Dana Point, California [3]. - Additionally, the company is set to present at Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference on May 29, 2025 [3]. - The Jefferies Global Healthcare Conference presentation is scheduled for June 5, 2025, at 1:25 pm ET, also available for virtual participation [3].

Core Points - Emergent BioSolutions Inc. will host a conference call on May 7, 2025, at 5:00 pm eastern time to discuss Q1 2025 financial results [1] - Participants can access the call via webcast or telephone, with advance registration required for telephone participation [2] - A replay of the conference call will be available on the Investors page of Emergent's website [3] Company Overview - Emergent BioSolutions has been dedicated to protecting and saving lives for over 25 years, focusing on public health preparedness [4] - The company provides life-saving solutions for various health threats, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4] - Emergent encourages engagement through its website and social media platforms [4] Investor and Media Contacts - Richard S. Lindahl serves as the Executive Vice President and CFO, with contact available for investor inquiries [5] - Assal Hellmer is the Vice President of Communications, available for media inquiries [5]